How do sirolimus-eluting and paclitaxel-eluting stents compare in patients with and without diabetes mellitus?

Antonio Colombo

This article has no abstract so we have provided the first paragraph of the full text.

There is a critical need to improve outcomes after PCI in patients with diabetes. Drug-eluting stents (DESs) are supposed to provide the most benefit in patients with diabetes because this population has a higher incidence of cardiac death and need for a second procedure when balloon angioplasty or bare-metal stents (BMSs) are used. At present, two DESs have demonstrated superiority compared with BMSs in a general population of patients: the Cypher^® stent and the Taxus^® stent.¹ When the question of DES efficacy is focused on patients with diabetes, two statements can be made: first, whatever difference might exist in outcomes between these two stents, the difference is clinically marginal (a different answer would have been evident by now); and second, we await a DES that is more effective in patients with diabetes.

ARTICLE NAVIGATION - ARTICLE TOOLS

• Full text
• Download PDF
• Send to a friend
• PDA services
• Permissions
• Rights and permissions
• Order commercial reprints

ISSUE NAVIGATION - THIS ISSUE

• Table of Contents
• Previous article
• Next article